NCT05099094View on ClinicalTrials.gov

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

September 30, 2025

Conditions
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Interventions
GENETIC

BD311

Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody

Trial Locations (1)

200032

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Eye & ENT Hospital of Fudan University

OTHER

lead

Shanghai BDgene Co., Ltd.

INDUSTRY